A recent study led by Usui et al. assessed the adverse event profile of brivaracetam as adjunctive therapy for focal-onset seizures in Asian adult patients. The research provides critical safety data relevant to this demographic, supporting informed clinical decision-making in epilepsy management across diverse populations. The findings contribute to optimization of antiseizure regimens with consideration of tolerability and patient-centered care in Asia.